Skip to content

MaxCyte MXCT Change in Deferred Revenue

Change in Deferred Revenue at other companies

Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$2.61M+80.2%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$1.9M+475%
PDE
Pro-Dex, Inc.PDEX
-$19K
Prime Medicine logo
Prime MedicinePRME
-$856K+40.5%

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's change in deferred revenue?
MaxCyte (MXCT) reported change in deferred revenue of -$327K in Q1 2026.
How has MaxCyte's change in deferred revenue changed year-over-year?
MaxCyte's change in deferred revenue increased by 75.3% year-over-year, from -$1.33M to -$327K.
What does change in deferred revenue mean?
Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.